Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6 months after obesity surgery.
Adult
Antifibrinolytic Agents
/ blood
Biomarkers
/ blood
Body Mass Index
Carboxypeptidase B2
/ blood
Female
Fibrin Clot Lysis Time
/ statistics & numerical data
Fibrinogen
/ analysis
Gastric Bypass
Humans
Male
Obesity, Morbid
/ blood
Plasminogen
/ analysis
Postoperative Period
Predictive Value of Tests
Preoperative Period
Randomized Controlled Trials as Topic
Regression Analysis
Sex Factors
Thromboplastin
/ analysis
Treatment Outcome
bariatric surgery
fibrinolysis
glucose
haemostasis
lipids
obesity
Journal
Clinical obesity
ISSN: 1758-8111
Titre abrégé: Clin Obes
Pays: England
ID NLM: 101560587
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
05
05
2020
revised:
02
07
2020
accepted:
14
07
2020
pubmed:
23
8
2020
medline:
13
7
2021
entrez:
23
8
2020
Statut:
ppublish
Résumé
Prothrombotic and metabolic variables are decreased after obesity surgery, and fibrin clot lysis is increased. It is unknown how fibrinolytic variables are affected, and whether fibrinolytic and metabolic changes predict the enhanced clot lysis. Study aims were to determine fibrinolytic biomarkers before and 6 months after Roux-en-Y gastric bypass (RYGB) and to identify predictors of the RYGB-induced increase in clot lysis. Women (n = 42) and men (n = 18) with obesity underwent RYGB, and factor XIII (FXIII), thrombin activatable fibrinolysis inhibitor (TAFI), plasminogen and plasmin inhibitor (PI) were measured before and 6 months after surgery. Regression analyses identified determinants of the RYGB-induced increase in clot lysis among changes in fibrinogen and in fibrinolytic and metabolic variables. Results showed that after RYGB, FXIII, TAFI, plasminogen and PI were reduced (P < .0005). Reductions in PI (β = -0.59) and fibrinogen (β = -0.35), together with age (β = -0.22) and male sex (β = 0.22), predicted the enhanced clot lysis with the model explaining 56% (P < .0005). Predictors of the reduction in PI were reductions in cholesterol (β = 0.37) and glucose (β = 0.29), together with male sex (β = -0.28), whereas reductions in fibrinogen were predicted by lowering of interleukin-6 (IL-6) (β = 0.32). In conclusion, fibrinolytic variables were reduced 6 months after RYGB. Targeting PI and fibrinogen, by reducing metabolic variables such as glucose, cholesterol and IL-6, has a profibrinolytic effect in obesity.
Substances chimiques
Antifibrinolytic Agents
0
Biomarkers
0
Fibrinogen
9001-32-5
Plasminogen
9001-91-6
Thromboplastin
9035-58-9
Carboxypeptidase B2
EC 3.4.17.20
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12397Informations de copyright
© 2020 World Obesity Federation.
Références
Di Cesare M, Bentham J, Stevens GA, et al. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387:1377-1396.
Afshin A, Reitsma MB, Murray CJL. Health effects of overweight and obesity in 195 countries. N Engl J Med. 2017;377:1496-1497.
Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci. 2009;54:1847-1856.
Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359-404.
Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:S64-S73.
Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122:3415-3422.
Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol. 2013;20:437-444.
Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. Thromb Haemost. 2013;110:669-680.
Vilahur G, Ben-Aicha S, Badimon L. New insights into the role of adipose tissue in thrombosis. Cardiovasc Res. 2017;113:1046-1054.
Hunt BJ. Hemostasis at extremes of body weight. Semin Thromb Hemost. 2018;44:632-639.
Bladbjerg EM, Stolberg CR, Juhl CB. Effects of obesity surgery on blood coagulation and fibrinolysis: a literature review. Thromb Haemost. 2020;120:579-591.
Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096.
Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1640-1649.
Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. Jama. 2012;307:56-65.
Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753-761.
Stolberg CR, Mundbjerg LH, Funch-Jensen P, Gram B, Juhl CB, Bladbjerg EM. Effects of gastric bypass followed by a randomized study of physical training on markers of coagulation activation, fibrin clot properties, and fibrinolysis. Surg Obes Relat Dis. 2018;14:918-926.
Sjoland JA, Sidelmann JJ, Brabrand M, et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost. 2007;98:339-345.
Undas A. Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost. 2014;112:32-42.
Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol. 2011;31:494-499.
Undas A, Ariens RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011;31:e88-e99.
Dunn EJ, Ariens RA, de Lange M, et al. Genetics of fibrin clot structure: a twin study. Blood. 2004;103:1735-1740.
Sidelmann JJ, Kluft C, Krug AH, Winkler U, Jespersen J, Gram JB. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women. Thromb Haemost. 2017;117:700-705.
Mundbjerg LH, Stolberg CR, Cecere S, et al. Supervised physical training improves weight loss after roux-en-Y gastric bypass surgery: a randomized controlled trial. Obesity. 2018;26:828-837.
Stolberg CR, Mundbjerg LH, Funch-Jensen P, Gram B, Bladbjerg EM, Juhl CB. Effects of gastric bypass surgery followed by supervised physical training on inflammation and endothelial function: a randomized controlled trial. Atherosclerosis. 2018;273:37-44.
Mundbjerg LH, Stolberg CR, Bladbjerg EM, Funch-Jensen P, Juhl CB, Gram B. Effects of 6 months supervised physical training on muscle strength and aerobic capacity in patients undergoing roux-en-Y gastric bypass surgery: a randomized controlled trial. Clin Obes. 2018;8:227-235.
Stolberg CR, Mundbjerg LH, Bladbjerg EM, Funch-Jensen P, Gram B, Juhl CB. Physical training following gastric bypass: effects on physical activity and quality of life-a randomized controlled trial. Qual Life Res. 2018;27:3113-3122.
Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood. 2011;117:6371-6374.
Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem. 1998;273:27220-27224.
Bryk AH, Siudut J, Broniatowska E, et al. Sex-specific alteration to alpha2-antiplasmin incorporation in patients with type 2 diabetes. Thromb Res. 2019;185:55-62.
Moroi M, Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem. 1976;251:5956-5965.
Hortin G, Fok KF, Toren PC, Strauss AW. Sulfation of a tyrosine residue in the plasmin-binding domain of alpha 2-antiplasmin. J Biol Chem. 1987;262:3082-3085.
Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes. 1983;32:680-684.
Ajjan RA, Gamlen T, Standeven KF, et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood. 2013;122:134-142.
Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48:1198-1206.
Dunn EJ, Philippou H, Ariens RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006;49:1071-1080.
Alzahrani SH, Hess K, Price JF, et al. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab. 2012;97:E2282-E2287.
Pieters M, Guthold M, Nunes CM, de Lange Z. Interpretation and validation of maximum absorbance data obtained from turbidimetry analysis of plasma clots. Thromb Haemost. 2020;120:44-54.
Neergaard-Petersen S, Hvas AM, Kristensen SD, et al. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thromb Haemost. 2014;112:1142-1150.
Gram J, Skov J, Bladbjerg EM, Sidelmann J, Jespersen J. Gender differences in fibrin polymerization and lysability of fibrin in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2016;25:292-297.
Ramanathan R, Sand NPR, Sidelmann JJ, Norgaard BL, Gram JB. Sex difference in clot lysability and association to coronary artery calcification. Biol Sex Differ. 2018;9(9):9.
Samuels J, Lawson PJ, Morton AP, et al. Prospective assessment of fibrinolysis in morbid obesity: tissue plasminogen activator resistance improves after bariatric surgery. Surg Obes Relat Dis. 2019;15:1153-1159.